Literature DB >> 19519501

Thalidomide chemotherapy-induced peripheral neuropathy: actual status and new perspectives with thalidomide analogues derivatives.

Sante Cundari1, Guido Cavaletti.   

Abstract

IMiDs compounds are a class of analogues of thalidomide, with greater immunomodulatory activity and a superior safety profile compared to the parent compound. They show substantial increase in potency and an interesting tolerability profile, primarily due to a decreased incidence of the most severe side effect of thalidomide, i.e. Chemotherapy-Induced Peripheral Neurotoxicity (CIPN). These novel aspects of the IMiDs compounds will be discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19519501     DOI: 10.2174/138955709788452595

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  5 in total

1.  Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy in Cancer Therapy Evaluation Program-sponsored phase I trials.

Authors:  Shun Kishimoto; Nobu Oshima; Matthew Rinker; Murali C Krishna; Naoko Takebe
Journal:  Eur J Cancer       Date:  2019-05-24       Impact factor: 9.162

Review 2.  Angiogenesis inhibitors: current strategies and future prospects.

Authors:  Kristina M Cook; William D Figg
Journal:  CA Cancer J Clin       Date:  2010-06-16       Impact factor: 508.702

3.  Editor's Highlight: Multiparametric Image Analysis of Rat Dorsal Root Ganglion Cultures to Evaluate Peripheral Neuropathy-Inducing Chemotherapeutics.

Authors:  Liang Guo; John Hamre; Sandy Eldridge; Holger P Behrsing; Facundo M Cutuli; Jodie Mussio; Myrtle Davis
Journal:  Toxicol Sci       Date:  2017-03-01       Impact factor: 4.849

Review 4.  Chemotherapy-induced peripheral neurotoxicity.

Authors:  Guido Cavaletti; Paola Marmiroli
Journal:  Nat Rev Neurol       Date:  2010-11-09       Impact factor: 42.937

Review 5.  Nurse self-evaluation of assessment of chemotherapy-induced peripheral neuropathy in patients with cancer.

Authors:  Constance Visovsky; Marilyn Haas; Beth Faiman; Sandra Kurtin; Anne Marie Shaftic; Elizabeth Lyden; Janique Rice
Journal:  J Adv Pract Oncol       Date:  2012-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.